Moderate riskFDA DrugClass II

Baxter MYXREDLIN insulin injection recalled for CGMP manufacturing deviations

Baxter Healthcare is recalling specific lots of MYXREDLIN (insulin human injection) due to deviations from current Good Manufacturing Practice (CGMP) standards during production. The affected lots were distributed in the US, Puerto Rico, and Chile. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Baxter recalls

What to do

  1. Check if your insulin matches one of the recalled lot numbers (NC188630, NC188708, NC188791, NC188845, NC188876, NC188968, NC193719, NC193849, NC194051, NC194105, or NC195171)
  2. Contact your pharmacy or healthcare provider if you have an affected lot
  3. Do not stop using insulin without medical guidance; ask your provider about an alternative

Is yours affected?

Compare your label or packaging with the recalled product.

Product
MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.
Sold in
Nationwide
Made for
Adults

This recall covers 17 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
1 Baxter Pkwy, N/A, Deerfield, IL, United States
Classification
Class II
Recall number
D-0806-2026

In the FDA's words

Description
MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12. CGMP Deviations Lot # NC188630, NC188708, NC188791, NC188845, NC188876, NC188968, Exp Date: 12/31/2027; Lot # NC193719, NC193849, Exp Date: 04/30/2028; Lot # NC194051, NC194105, Exp Date: 05/31/2028; Lot # NC195171, Exp Date: 06/30/2028. Distribution: US Nationwide; Puerto Rico; and Chile. Affected quantity: N/A
Hazard
CGMP Deviations

17 products in this recall

Baxter IV drug bags recalled for manufacturing quality issues

Baxter is recalling 17 intravenous (IV) drug products for manufacturing quality problems, called CGMP deviations, which are lapses in the required production standards. The products include vancomycin, daptomycin, clindamycin, famotidine, dexmedetomidine, vasopressin, pantoprazole, insulin, nicardipine, and amiodarone, plus the brand names Myxredlin, CARDENE IV, and Nexterone. They were distributed nationwide, in Puerto Rico, and in Chile, and no injuries have been reported.

The agency lists each product separately. Check every one you might have.

More from Baxter

See all

Related topics

OtherDrugsSold nationwideMore from FDA Drug